Navigation Links
Brain Tumor Vaccine Shows Promise in Early Trial
Date:4/17/2012

By Maureen Salamon
HealthDay Reporter

TUESDAY, April 17 (HealthDay News) -- A vaccine made from brain cancer patients' own tumor cells led to a nearly 50 percent improvement in survival times for those stricken with glioblastoma multiforme, the same malignancy that claimed the life of U.S. Sen. Edward Kennedy, a new study suggests.

A phase 2 multicenter trial of about 40 patients with recurrent glioblastoma -- an aggressive brain cancer that typically kills patients within 15 months of diagnosis -- showed that the vaccine safely increased average survival to nearly 48 weeks, compared with about 33 weeks among patients who didn't receive the treatment. The six-month survival rate was 93 percent for the vaccinated group, compared with 68 percent for 86 other glioblastoma patients, who were treated with other therapies.

"We've done a lot of things for this kind of tumor in the last 40 or 50 years, all variations on different chemotherapies that haven't really panned out," said Dr. Jonas Sheehan, director of neuro-oncology at the Penn State Cancer Institute, who was not involved in the study. "What we've known needed to happen for a while now is a revolution -- a totally new way of approaching these tumors. This is an example of a totally new paradigm."

The study is scheduled to be presented Tuesday at the annual meeting of the American Association of Neurological Surgeons (AANS), in Miami.

About a quarter of the 18,500 brain tumors diagnosed each year are glioblastomas, which are more common in men and typically occur between the ages of 50 and 70, according to the AANS. Kennedy died of the malignancy in 2009, 15 months after his diagnosis. Surgery, radiation and chemotherapy are among the standard treatment options.

The vaccine used in the trial, known as HSPPC-96, was created with tumor cells from patients who had undergone surgery to remove as much tumor as possible. The vaccine was then injected into their bodies to induce an immune response against the tumor, said lead investigator Dr. Andrew Parsa, vice chairman of neurological surgery at University of California, San Francisco. Side effects among participants were minimal.

"It's the concept of chronic therapy, to turn this into a chronic disease like hypertension and diabetes," said Parsa, who noted that no drug companies funded the study. "It's the only therapy in the clinical realm that has a reasonable chance of doing this, because we can't give patients chemotherapy [because of toxicity] for unlimited amounts of time."

Parsa said the vaccine's impact, if validated with a randomized study in the near future, could be a "total game-changer."

Added Sheehan: "The hope is that we'll go from a survival of 15 months to a meaningful difference. We're looking to go from 15 months to five years, a quantum leap forward."

Because this study was to be presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

More information

Visit the American Association of Neurological Surgeons for more on glioblastomas.

SOURCES: Andrew Parsa, M.D., Ph.D., professor and vice chairman, neurological surgery, University of California, San Francisco; Jonas Sheehan, M.D., director, neuro-oncology, Penn State Cancer Institute, Hershey, Pa.; April 17, 2012, presentation, abstract, American Association of Neurological Surgeons, annual meeting, Miami


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Football-related catastrophic brain injuries on the rise
2. Researchers Map Brain Regions Linked to Intelligence
3. Nonsurgical Method to Measure Brain Pressure Shows Promise
4. Dental X-Rays May Be Linked to Benign Brain Tumors
5. Brain Falters Near End of Life, but Games, Puzzles Might Slow Decline
6. Why is traumatic brain injury increasing among the elderly?
7. UCLA Brain Injury Research Center gets NCAA funding for research on sports concussions
8. Epilepsy Leads to More Brain Abnormalities Over Time
9. Study Suggests Vaccine May Help Kids With Brain Cancer
10. Our brains on food: From anorexia to obesity and everything in between
11. Northwestern study compares endovascular brain aneurysm repair devices
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Brain Tumor Vaccine Shows Promise in Early Trial
(Date:12/2/2016)... CO (PRWEB) , ... December 02, 2016 , ... Advanced ... announced it has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief ... for Advanced, Inc. , Jason brings extensive financial and operational leadership experience to ...
(Date:12/2/2016)... Raleigh, NC (PRWEB) , ... December 02, 2016 , ... ... the Open Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare ... plan (Part C) or prescription drug plan (Part D) need to make changes during ...
(Date:12/2/2016)... ... 02, 2016 , ... Mediaplanet’s newest campaign, “Digestive Heath,” hits ... proof that attitude and determination can combine into the most remarkable achievements. Over ... holidays. This campaign will offer patients a new-found hope, by seizing the opportunity ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is ... USA Today, which covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that ... “We are prolonging life 6 years in the last 3 decades,” says Dr. ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... veterinarian diagnostic imaging systems and the first company to offer robotic imaging ... Heart at their tradeshow booth # 941 for the American Association of Equine ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Dec. 2, 2016 Lianluo Smart Limited ... "the Company") which develops, markets and sells medical ... China and international markets, recently ... and Treatment New Progress Forum, co-hosted by the ... Province , Guangdong Provincial People,s Hospital and ...
(Date:12/2/2016)... Dec. 1, 2016 The concept of rare diseases ... given to this sector has been taking shape in ... the political aspects and initiatives related to orphan medicinal products ... the level of member states individually. Many member states in ... the space of orphan medicinal products, the result of which ...
(Date:12/2/2016)... Allergan plc (NYSE: AGN ), a ... previously announced Accelerated Share Repurchase (ASR) Program. Logo - ... ... previously announced, the Company entered into a variable tenor ASR ... repurchase $10 billion of its ordinary shares. Approximately 40.5 million ...
Breaking Medicine Technology: